Tomaka F, et al. Long-term data from APPROACH: Phase 1/2a randomized, double-blind, placebo-controlled study evaluating safety/tolerability and immunogenicity of vaccine regimens using combinations of Ad26.Mos.HIV, MVA-mosaic and gp140 envelope protein. AIDS 2018.
Klinisch bewijs binnen handbereik met behulp van AI
mei 2024 | Virale infecties